{"id":"W1828063937","doi":"10.1007/s40121-015-0071-0","title":"Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada","year":2015,"lang":"en","type":"article","venue":"Infectious Diseases and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"ViiV Healthcare","keywords":"Dolutegravir; Medicine; Atazanavir; Ritonavir; Raltegravir; Elvitegravir; Efavirenz; Rilpivirine; Abacavir; Cost effectiveness; Darunavir; Cobicistat; Adverse effect; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Virology; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003718465,0.0002068762,0.0004075046,0.0001318683,0.00002940164,0.000009504972,0.00001921991,0.00003472051,0.00001012783],"category_scores_gemma":[0.00001378561,0.0001445969,0.00003641386,0.0001725394,0.00004414542,0.00006690784,0.0000090781,0.0000292479,0.000001020055],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00109474,"about_ca_system_score_gemma":0.0007523198,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.3780985,"about_ca_topic_score_gemma":0.238561,"domain_scores_codex":[0.9991559,0.00009129869,0.0001845488,0.0002447724,0.0001271639,0.0001963565],"domain_scores_gemma":[0.9994746,0.0001009035,0.00005079277,0.0001127553,0.00004802196,0.0002129648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009609486,0.001228809,0.9540674,0.00001394463,0.0001118692,0.00006407915,0.001236581,0.000007899062,0.00002042231,0.00002425958,0.000008894013,0.04225486],"study_design_scores_gemma":[0.02326648,0.001184111,0.9733114,0.00008180988,0.00004002529,0.000006443279,0.0006009354,0.00003508815,0.0005089212,0.0001253334,0.0007032026,0.0001363016],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967586,0.001611257,0.000001558416,0.00004432452,0.00006271806,0.001167551,0.00004906425,0.00001311645,0.0002917803],"genre_scores_gemma":[0.9971733,0.002283454,0.000009715349,0.00002555678,0.00001174662,0.0003329246,0.00007145089,0.00001319572,0.00007865477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1395375,"threshold_uncertainty_score":0.7753333,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02564710316898824,"score_gpt":0.2825397717375404,"score_spread":0.2568926685685522,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}